Legend/Legend Biotech presented first-in-human data for LB-2501, a CD19/CD20 dual-targeting CAR T designed for an off-the-shelf approach with no lymphodepletion, at EHA2026. Investigators reported outcomes from 12 treated participants with relapsed or refractory B-cell non-Hodgkin lymphoma, with six patients treated at the higher dose level showing responses including complete remissions. Safety data described adverse events up to grade two and no neurotoxicity to date, with CEO Ying Huang characterizing the tolerability profile as a “pleasant surprise” compared with typical autologous CAR T experience. The program is framed as a potential shift toward outpatient-style delivery. The update also followed other cell therapy presentations at major meetings, underscoring continued momentum in engineered CAR T and related immune cell approaches targeting lymphoma and myeloma.